Test Price
2,800 AEDโ Home Collection Available
ATR Gene Cutaneous Telangiectasia and Cancer Syndrome, Familial Genetic Test in UAE
Executive Summary & Core Metrics
The ATR gene familial test utilises next-generation sequencing to identify pathogenic variants associated with cutaneous telangiectasia and hereditary cancer predisposition. This analysis delivers 99.9% diagnostic sensitivity through ISO 9001:2015 certified processing, enabling early risk stratification and personalised surveillance for dermatological and oncological manifestations. Premium logistics include VIP mobile phlebotomy with temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM, alongside telephonic post-test clinical guidance for result interpretation. Direct billing verification is accessible via WhatsApp at +971 54 548 8731.
- Diagnostic Accuracy: 99.9% Sensitivity via ISO 9001:2015 Certified Processing
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The ATR gene familial test screens for pathogenic variants linked to cutaneous telangiectasia and hereditary cancer predisposition. This NGS-based analysis provides comprehensive coverage of the entire coding region, allowing early risk stratification and personalised surveillance for dermatological and oncological manifestations. The assay employs targeted deep sequencing with proprietary bioinformatics, achieving coverage greater than 200x across all coding exons to detect even low-level mosaicism. All pathogenic classifications follow ACMG guidelines and are double-verified through independent reviewers.
| Feature | Our Test ATR NGS | Closest Alternative Single-Gene Sanger |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity; full exon capture | Approximately 95% per exon; may miss deep intronic variants |
| Method | Next-Generation Sequencing NGS | Capillary Sanger Sequencing |
| Speed | 3โ4 Weeks with expedited reporting | 6โ8 Weeks typical |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh – Consultant Medical Genetics DHA Registration ID: 9294403 notes: A confirmed ATR pathogenic variant does not equate to an immediate cancer diagnosis; it indicates a need for tailored screening and surveillance. Patients must arrange a genetic counselling follow-up to integrate results with personal and family history. Clinical correlation remains paramount for appropriate risk management.
Medication Advisory
Do not discontinue any prescribed medication without consulting your doctor. Certain drugs, including antiplatelets and anticoagulants, may require adjustment before blood collection only under direct medical supervision. Always consult your referring physician before scheduling your sample collection.
Exclusion Criteria and Emergency Red Flags
Do not proceed without physician clearance if any of the following apply:
- Active severe infection or febrile illness with temperature above 38.5ยฐC
- Known bleeding diathesis or inability to temporarily stop anticoagulants under medical guidance
- Severe anaemia or recent major surgery less than 4 weeks prior
- Pregnancy beyond routine venipuncture requiring specialist consent
Seek emergency care if you experience:
- Sudden onset of extensive telangiectatic bleeding or visceral haemorrhage
- Rapid development of new, ulcerating skin lesions
- Unexplained severe headache or neurological symptoms possibly indicating cerebral involvement
Patient FAQ & Clinical Guidance
1. What does a positive ATR NGS result mean for my cancer risk?
A positive result indicates a confirmed pathogenic variant that increases lifetime risk for specific cancers, necessitating tailored surveillance. It does not guarantee cancer will develop, but it does place you in a high-risk category. Your dermatologist and oncologist will recommend a personalised screening plan often including skin examinations, imaging, and possibly prophylactic measures. Genetic counselling is essential to interpret the exact risk and inform family members.
2. How accurate is the NGS test for detecting ATR mutations?
Clinical validation demonstrates 99.9% analytical sensitivity and specificity for single-nucleotide variants and small indels in the ATR gene. Using targeted deep sequencing with proprietary bioinformatics, our laboratory achieves coverage greater than 200x across all coding exons, ensuring even low-level mosaicism is detected. All pathogenic classifications follow ACMG guidelines and are double-verified by independent reviewers.
3. Does home collection meet the same quality as an in-lab blood draw?
Our ISO-certified mobile phlebotomy uses identical vacuum collection systems and cold-chain transport, preserving sample integrity for NGS analysis. A trained DHA-licensed phlebotomist arrives with pre-iced transport containers maintaining 2โ8ยฐC, and the specimen reaches the processing facility within four hours. DNA extraction begins immediately, ensuring high molecular weight DNA free of degradation. This process is validated under ISO 9001:2015.
4. What pre-test preparations are required before sample collection?
A genetic counselling session to draw a pedigree chart of family members affected with ATR-related conditions is strongly advised before sample collection. Provide a detailed clinical history of the patient. Blood 3โ5 mL in EDTA tube, extracted DNA minimum 1 ยตg, or one drop of blood on an FTA card are accepted specimen types. If you are on anticoagulants or antiplatelet medication, consult your referring physician before scheduling. Avoid heavy physical exertion and alcohol for 24 hours before the draw.
UAE Regulatory & Data Privacy Adherence
Your data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection PDPL and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory operates under DHA Facility License Number 1143 and maintains ISO 9001:2015 certification. All genetic information is handled with strict confidentiality and used solely for diagnostic and treatment purposes in accordance with UAE federal regulations.
Clinical & Logistical Metadata
| Test Name | ATR Gene Cutaneous Telangiectasia and Cancer Syndrome, Familial Genetic Test |
| Price AED | 2,800 |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood EDTA, Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing NGS |
| ICD-10-CM Code | Z15.09 |
| LOINC Code | 81262-7 |
| DHA Facility License & Laboratory Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians